BBSRC invests £48m in Babraham Institute to advance lifelong health research
The funding will help to support research across epigenetics, immunology and cell signalling
Read More
Tag: cell signalling
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
